German Treyger, DO
Dermatology · Wyandotte, MINPI 1487002119
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $49,760 of the $74,853 with a category attached, or 66.5%. Galderma Laboratories, L.p. accounts for 75.4% of it on its own, with 36 other manufacturers making up the rest. 2025 is the largest year on record at $38,148, more than ten times the $1,382 reported in 2019. Among dermatology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,055 payments — averaging $70.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$56K
- Novartis$2K
- AbbVie$2K
- Sun Pharmaceutical Industries Inc.$2K
- Johnson & Johnson$1K
- E.r. Squibb & Sons, L.L.C.$1K
- plus $10K from 31 others
What the payments were for
- Speaking & faculty fees$49,76066%
- Travel & lodging$3,6785%
- Food & beverage$20,40227%
- Education$1,0131%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 130 | $56,437 |
| Novartis | 130 | $1,981 |
| AbbVie | 87 | $1,876 |
| Sun Pharmaceutical Industries Inc. | 77 | $1,568 |
| Johnson & Johnson | 76 | $1,437 |
| E.r. Squibb & Sons, L.L.C. | 54 | $1,331 |
| Amgen | 53 | $1,241 |
| Sanofi | 47 | $1,239 |
| Regeneron Healthcare Solutions, Inc. | 43 | $1,204 |
| Incyte Corporation | 55 | $1,016 |
| UCB, Inc. | 41 | $911 |
| Lilly USA, LLC | 49 | $852 |
| Pfizer | 33 | $637 |
| LEO Pharma Inc. | 59 | $605 |
| Dermavant Sciences, Inc. | 30 | $559 |
| Arcutis Biotherapeutics, Inc. | 26 | $484 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 12 | $317 |
| Sanofi-aventis U.S. LLC | 2 | $172 |
| Organon | 8 | $144 |
| Genentech USA, Inc. | 6 | $121 |
| EPI Health, LLC | 4 | $99 |
| Bristol Myers Squibb | 4 | $73 |
| Almirall LLC | 4 | $72 |
| Dermira, Inc. | 3 | $58 |
| Journey Medical Corporation | 3 | $56 |
| Fresenius Kabi USA, LLC | 2 | $48 |
| Revance Therapeutics, Inc. | 2 | $45 |
| Botanix SB Inc | 2 | $43 |
| AstraZeneca | 2 | $43 |
| Mayne Pharma Commercial LLC | 4 | $41 |
| LNHC, Inc | 1 | $40 |
| Cipher Pharmaceuticals US LLC | 1 | $32 |
| Kyowa Kirin, Inc. | 1 | $18 |
| VYNE Pharmaceuticals Inc. | 1 | $15 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $14 |
| Biofrontera Inc. | 1 | $13 |
| Strata Skin Sciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$74,853 in reported general payments places this provider in the 90th percentile of 404 dermatology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 44 | $210,411 |
| Dupixent SyringeDupilumab | 35 | $130,944 |
| Cosentyx Unoready PenSecukinumab | 14 | $120,491 |
| Dupixent PenDupilumab | 17 | $62,474 |
| Metronidazole | 108 | $6,186 |
| Tacrolimus | 41 | $4,577 |
| Clobetasol Propionate | 170 | $4,184 |
| Ketoconazole | 275 | $3,890 |
| Ivermectin | 18 | $3,759 |
| Ciclopirox | 100 | $3,283 |
| Fluticasone Propionate | 76 | $2,653 |
| Triamcinolone Acetonide | 119 | $1,829 |
| Mometasone Furoate | 138 | $1,808 |
| Doxycycline Hyclate | 131 | $1,645 |
| Fluorouracil | 32 | $1,586 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $1,241 | $210,41144 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 404 dermatology providers in Michigan.
Other dermatology in Wyandotte
- Linda Stein GoldWest Bloomfield$3.3M
- Kristi HawleyCaledonia$2.2M
- David AltmanWarren$1.9M
- Michael SiegelWaterford$708K
- Johann GudjonssonAnn Arbor$535K
- Michael DormanWest Bloomfield$433K
- Steven DaveluyDearborn$350K
- Benjamin WorkmanMidland$284K
- Diana WestgateKalamazoo$252K
- Christofer BuattiAuburn Hills$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.